Drug Discovery & Pharmaceuticals

RSS

Researchers discover osteogenetic oligodeoxynucleotide that promotes bone differentiation

Bone tissue homeostasis is maintained by a balance between bone formation by osteoblasts and bone resorption by osteoclasts.

23 May 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

Micro Products with Macro Impact; The Role of Microplate Readers in Life Sciences

In this interview, we speak to Martin Mangold, an applications specialist at BMG LABTECH, about their microplate readers and the essential role they play within life sciences research.

From BMG LABTECH GmbH 19 May 2022

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research.

18 May 2022

Recombinant protein vaccine stands up to SARS-CoV-2 variants

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 May 2022

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

A recent article posted to the bioRxiv* preprint server demonstrated structural underpinnings of the neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants by 002-S21F2, an extensive SARS-CoV-2 neutralizing antibody.

18 May 2022

Impact of cannabidiol on cellular innate immune responses to SARS-CoV-2 genes

A new study published in the journal Life Sciences has focused on examining the effects of ORF8 and ORF10 genes and SARS-CoV-2 Membrane (M) protein on apoptosis.

17 May 2022

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

Researchers from Naval Medical University have been investigating anisodamine, used in traditional Chinese medicine, to inhibit SARS-CoV-2 infection in cellular models. The study is published in the journal Biochemical and Biophysical Research Communications.

17 May 2022

Identifying new chemicals with greater effectiveness, safety than quisinostat

Announcing a new review article publication for Acta Materia Medica journal. In this article the authors use medicinal chemistry methods to identify new chemical entities with greater effectiveness and safety than quisinostat.

17 May 2022

Neutralization of SARS-CoV-2 by plant-made neutralizing monoclonal antibodies

In a recent study published in the journal Vaccines, researchers developed plant-based monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

17 May 2022

Mice live longer with nasal gene therapy

In a recent study published in the Proceedings of the National Academy of Sciences journal, researchers assessed the efficiency of a novel intranasal and injectable therapy in improving life expectancy.

17 May 2022

Broad-spectrum polymeric antivirals against SARS-CoV-2

In a recent study published in the journal Advanced Science, researchers evaluated the potential and applicability of macromolecular viral inhibitors against respiratory viral pathogens.

17 May 2022

New drug inhibits growth of the most aggressive meningiomas

When a specific non-metastatic brain tumor — a meningioma — recurs after surgery and radiation treatment, a patient is normally out of options. No drugs are approved for these aggressive tumors, which occur in up to 20 percent of cases and can lead to patient disability or even death.

16 May 2022

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

15 May 2022

An Ad5 vectored COVID vaccine expressing an S1-N fusion protein

In a recent study posted to the bioRxiv* preprint server, researchers characterized the development of multiple adenovirus-vectored and subunit recombinant protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates.

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

The promise of RNA medicine is targeted and personalized

The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.

11 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022